Should every adult with type 2 diabetes be prescribed an SGLT2 inhibitor regardless of renal function, albuminuria, infection risk, or pregnancy status?

You Are Correct: SGLT2 Inhibitors Are NOT for Every Adult with Type 2 Diabetes

Not all adults with type 2 diabetes should receive an SGLT2 inhibitor—the decision must be based on specific clinical criteria including cardiovascular/kidney disease status, renal function thresholds, infection risk, and absolute contraindications. 1

Risk-Stratified Approach to SGLT2 Inhibitor Use

Strong Indications (Should Receive SGLT2i)

Adults with type 2 diabetes SHOULD receive SGLT2 inhibitors when they have:

• Heart failure (reduced OR preserved ejection fraction) 1, 2
• Established CKD with eGFR 20-60 mL/min/1.73 m² and/or albuminuria 1, 3
• Established atherosclerotic cardiovascular disease (ASCVD) 2
• Very high or high risk of CKD progression 4

These recommendations are based on mortality and morbidity benefits demonstrated in major trials (CREDENCE, DAPA-CKD, EMPEROR trials) 3, 5.

Weak or No Indication

Adults with type 2 diabetes should NOT routinely receive SGLT2 inhibitors when they have:

• Low cardiovascular risk (≤3 cardiovascular risk factors, no established CVD/CKD): Weak recommendation AGAINST 6, 7
• Moderate risk (>3 risk factors but no established CVD/CKD): Only weak recommendation FOR 6, 7

The 2024 ADA guidelines emphasize a person-centered shared decision-making approach that considers individual glycemic goals, weight goals, and comorbidities—not blanket prescribing 1.

Absolute and Relative Contraindications

Do NOT Prescribe SGLT2 Inhibitors When:

1. Severe renal impairment: eGFR <20 mL/min/1.73 m² (limited safety data) 5, 8
2. Type 1 diabetes: Currently contraindicated 8
3. Pregnancy or breastfeeding: Not studied, avoid use
4. Active diabetic ketoacidosis: Absolute contraindication
5. Recurrent severe genitourinary infections: Relative contraindication given 2-10% infection risk 9, 10

Exercise Caution With:

• High infection risk populations: Uncircumcised males, women with recurrent genital mycotic infections (10-15% risk), immunocompromised patients 5, 9, 8, 10
• Volume depletion risk: Patients on high-dose diuretics, elderly with poor oral intake 5
• Insulin-requiring patients: Higher euglycemic ketoacidosis risk—maintain at least low-dose insulin and implement sick day protocols 5, 9

Renal Function Considerations

The glycemic benefits of SGLT2 inhibitors diminish significantly at eGFR <45 mL/min/1.73 m², though cardiovascular and renal protective effects persist 1.

• eGFR ≥20 mL/min/1.73 m²: Can initiate SGLT2i for cardiorenal protection 5
• eGFR <30 mL/min/1.73 m²: GLP-1 RA preferred for glycemic management 1
• eGFR <20 mL/min/1.73 m²: Very limited data, generally avoid 8

Common Pitfalls to Avoid

1. Prescribing for glycemic control alone in low-risk patients: The primary benefit is cardiorenal protection, not glucose lowering 6, 7
2. Discontinuing when eGFR drops after initiation: The initial eGFR decline (up to 15%) is expected and reversible—continue unless eGFR falls below 20 or patient develops intolerance 5
3. Ignoring infection risk factors: Screen for history of recurrent genitourinary infections before prescribing 5, 9, 10
4. Failing to implement sick day protocols: Must educate patients to hold SGLT2i during acute illness to prevent ketoacidosis 5, 9

The Evidence Hierarchy

The 2024 BMJ guideline provides the most granular risk stratification 4:

• Very high risk CKD: Strong recommendation FOR
• High risk CKD: Strong recommendation FOR
• Moderate risk CKD: Weak recommendation FOR
• Low risk CKD: Weak recommendation FOR

This contrasts sharply with blanket prescribing—the strength of recommendation directly correlates with baseline risk and anticipated absolute benefit.

Practical Algorithm

Step 1: Assess cardiovascular/kidney disease status

• Heart failure? → Prescribe SGLT2i
• CKD with eGFR 20-60 or albuminuria? → Prescribe SGLT2i
• Established ASCVD? → Prescribe SGLT2i

Step 2: If none of above, assess cardiovascular risk factors

• ≤3 risk factors → Do NOT routinely prescribe

• 3 risk factors → Consider prescribing (shared decision-making)

Step 3: Check for contraindications

• eGFR <20? → Do not prescribe
• Type 1 diabetes? → Do not prescribe
• Recurrent genitourinary infections? → Reconsider
• High ketoacidosis risk? → Implement safeguards or choose alternative

Step 4: Monitor appropriately

• Genital hygiene counseling
• Sick day protocol education
• Volume status assessment
• Ketone monitoring if high risk